Intervention Group:Camrelizumab+apatinib+TACE

A randomized controlled clinical trial of camrelizumab, apatinib mesylate combined with TACE versus apatinib mesylate combined with TACE for hepatocellular carcinoma with high recurrence risk after hepatectomy

A randomized controlled clinical trial of camrelizumab and apatinib combined with TACE versus apatinib combined with TACE for advanced unresectable hepatocellular carcinoma